Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data before initiating OPTIMIZE-2 study in H1 2023Lund, Sweden, July 12, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Progresses Clinical Programs Towards Key Readouts “We continued to make encouraging clinical progress with our leading drug candidates this quarter and we are looking ahead to key readouts from our OPTIMIZE-1 and ATOR-1017 clinical trials due in the second half of the year. We also expanded our board with two new